SecBot SecBot
PRESS-RELEASE ·Filed May 15, 2026

PPBT

Purple Biotech Ltd.
NEUTRAL
Impact 4/10
Horizonmonths Processed6mo ago WireGlobeNewswire
Press release · Earnings
Actionable Insight • Neutral

Monitor for partnering or financing announcements given the $6.4M cash runway into 2027 and the company's statement that further development of CM24 and NT219 requires partnering or additional investment. The CAPTN-3 platform's preclinical data and AI collaboration are key catalysts to watch for IND filings and clinical trial initiations.

DirectionNeutral
Confidencemedium
Horizonmonths

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$3.94
T+0 close · May 15, 2026 · via day close
Latest settled
−60.66%
T+60 · $1.55
Vs SPY
−65.18%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 15 $3.94entry
  2. T+1 · 6mo ago −4.06%α −4.00% · $3.78
  3. T+5 · 6mo ago −26.90%α −27.87% · $2.88
  4. T+20 · 5mo ago −57.11%α −59.23% · $1.69
  5. T+60 · 3mo ago −60.66%α −65.18% · $1.55

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Purple Biotech reported Q1 2026 net loss of $0.1M, significantly narrower than the $0.5M loss in Q1 2025, driven by $2.2M in non-cash finance income from warrant revaluation. The company had $6.4M in cash as of March 31, 2026, expected to fund operations into 2027. The press release focused on preclinical data for its CAPTN-3 platform and IM1240 tri-specific antibody, with no revenue reported.

Key Financial Metrics

EPS
−$0.09
est −$0.38 · +76.3%
Revenue
$0.00
est $0.00
Rating
beat

Key Facts

  • Net loss of $0.1M for Q1 2026 vs $0.5M in Q1 2025, improvement driven by $2.2M non-cash finance income from warrant fair value changes
  • Adjusted operating loss (non-IFRS) was $2.1M, up from $1.3M in Q1 2025
  • Cash and cash equivalents and short-term deposits of $6.4M as of March 31, 2026, expected to provide runway into 2027
  • No revenue reported; company is clinical-stage with no approved products
  • Lead program CAPTN-3 (IM1240) advancing toward first-in-human studies in 2027
  • Expanded collaboration with Converge Bio for generative AI-driven antibody design
  • Established CAPTN-3 Scientific Advisory Board

Financial Impact

Cash burn of $3.1M in operating cash flow during Q1 2026; $6.4M cash position provides runway into 2027

cashoperating lossnet loss

Risk Factors

  • Cash runway limited to 2027; additional financing likely needed before reaching profitability
  • Preclinical-stage pipeline with no approved products; high clinical development risk
  • Dependence on successful partnering for legacy assets CM24 and NT219
  • Net loss improvement driven by non-cash finance income, not operational improvement

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3295734

Track record

14 reports on PPBT

Performance horizon

The track record builds as more bullish or bearish reports settle.

Filters
  1. Nov 12, 20264d ago SC 13G Neutral 3/10 Entry $1.56 Now $1.68 +7.69% settles Feb 10
  2. Nov 12, 20265d ago EFFECT Neutral 3/10 Entry $1.56 Now $1.68 +7.69% settles Feb 10
  3. Nov 10, 20266d ago SC 13G/A Neutral 2/10 Entry $1.49 Now $1.68 +12.75% settles Feb 9
  4. Oct 29, 202618d ago Press Release Neutral 3/10 Entry $1.09 Now $1.68 +54.13% settles Jan 27
  5. Oct 5, 20266w ago 6-K Neutral 2/10 Entry $1.47 Now $1.68 +14.29% settles Dec 31
  6. Sep 9, 20269w ago 6-K Neutral 2/10 Entry $1.74 Now $1.68 −3.45% settles Dec 4
  7. Sep 2, 202610w ago 6-K Neutral 3/10 Entry $1.98 Now $1.68 −15.15% settles Nov 27
  8. Aug 10, 202614w ago 6-K Neutral 4/10 Entry $1.55 to $1.22 Now $1.68 +8.39% ▼ −21.61% −21.13% vs SPY
  9. Aug 7, 202614w ago 6-K Neutral 4/10 Entry $1.43 to $1.22 Now $1.68 +17.48% ▼ −14.69% −12.55% vs SPY
  10. May 15, 202626w ago Press Release Neutral 4/10 Viewing Entry $3.94 to $1.55 Now $1.68 −57.36% ▼ −60.66% −65.18% vs SPY
Showing 10 of 14

US Market Status

Market Closed · Opens in 6h 38m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 15, 2026